Join
Live feed
·
PRReleasevia Quantisnow
Nexentis Technologies Inc. logo

Nexentis Announces MitoCareX Bio Achieves Key R&D Milestone, Generating a Substantially Improved Hit Molecule on the Path to Pre-Clinical Development

ByQuantisnow·Wall Street's wire, on your screen.
NXTS· Nexentis Technologies Inc.
Industrials

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track NXTS (Nexentis Technologies Inc.) and more on Quantisnow.